InVitro International reported a 5.3% increase in sales for Q2 FY 2026, reaching $206,840, and a 14.7% rise in net income compared to the same quarter last year. However, year-to-date sales are down 11.6% compared to the first half of FY 2025, and net income for the first half of FY 2026 is 42.8% lower than the previous year. The CEO highlighted progress in the company's strategic direction and optimism about growing global acceptance of their non-animal testing technologies. InVitro aims to continue its streak of profitability while expanding its market reach amid changing regulatory policies.
SpaceX shares have dropped over 30% since their June 2026 IPO, with investors advised to consider buying between August and October 2026 for a better entry point. The company's first public earnings report on August 4 could trigger further price vola...
The Davis Select U.S. Equity ETF (DUSA) has modestly outperformed the IVV ETF year-to-date, despite its portfolio focusing on low-beta, high earnings yield stocks. However, analyst Vasily Zyryanov maintains a neutral stance and expects DUSA to underp...
Ethereum is showing signs of a strong comeback against Bitcoin, supported by a technical reversal, renewed institutional ETF inflows totaling $103 million weekly, and dominance in the $17 billion tokenization market. Analysts highlight Ethereum's pri...
Coca-Cola Europacific Partners (CCEP) received a buy rating due to its diversified growth strategies beyond just raising prices. The company's strong local bottling and distribution network supports volume growth through energy drinks, zero-sugar opt...
Dogecoin is showing signs of a technical reversal as it approaches a key support level near $0.056. The TD Sequential indicator on the monthly chart has triggered a buy signal, suggesting a possible rebound to $0.16, with a broader resistance target ...
